Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

Citi analyst David Lebowitz has maintained their bullish stance on MDGL stock, giving a Buy rating yesterday.Invest with Confidence: Follow ...

Chief Commercial Officer of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a $6.79 billion market cap biopharmaceutical ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

Shares of Madrigal Pharmaceuticals MDGL lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises only its ...

CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...

Below is Validea's guru fundamental report for MADRIGAL PHARMACEUTICALS INC (MDGL). Of the 22 guru strategies we follow, MDGL rates highest using our Contrarian Investor model based on the ...

Shares of Madrigal Pharmaceuticals MDGL lost 9.7% on Tuesday as the investors were not impressed by its preliminary fourth-quarter and full-year 2024 results. The company’s top line comprises ...